Lactobacillus Strains Mucosal Colonization Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions of Lactobacilli strains are not sufficiently efficient in recolonizing in vivo, and there is a need for strains with enhanced abilities to colonize mucosal membranes for the treatment or prevention of vaginal infections, urinary-tract infections, and gastrointestinal diseases.
Innovation Solution
Development of Lactobacillus gasseri strain Lba EB01, Lactobacillus rhamnosus strain Lbp PB01, Lactobacillus acidophilus strain Lba EB02, Lactobacillus plantarum strain Lbpl PB02, and Lactobacillus strain Lbxx PB03, which exhibit strong adherence to mucosal membranes, produce hydrogen peroxide, and show bile and acid stability, along with the use of mucous adhesive excipients to enhance colonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional Lactobacilli strains are used in pharmaceutical compositions, then the basic probiotic function is provided, but the colonization efficiency on mucosal membranes is insufficient
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing specific Lactobacillus strains (L. gasseri, L. rhamnosus, L. acidophilus, L. plantarum) with optimized physiological parameters including bile salt resistance, acid stability, and enhanced adhesion properties. These parameter optimizations enable the strains to survive gastrointestinal conditions and effectively colonize mucosal membranes, resolving the contradiction between basic probiotic function and colonization efficiency.
2Object-affected harmful factors
If Lactobacilli strains are administered to treat infections, then therapeutic benefit is provided, but the ability to suppress pathogenic bacteria and Candida albicans is insufficient
Solution Approach 1:
The patent converts the competitive interaction between Lactobacilli and pathogenic bacteria into a beneficial therapeutic effect. The selected strains produce bacteriocins and organic acids that inhibit pathogens while simultaneously competing for adhesion sites, thereby converting microbial competition into a protective mechanism against vaginal, urinary-tract, and gastrointestinal infections.
Solution Approach 2:
The patent optimizes the physiological parameters of the Lactobacillus strains to enhance their inhibitory activity against pathogens. The strains are characterized for their ability to produce hydrogen peroxide, bacteriocins, and organic acids under specific cultivation conditions, creating a multi-factorial inhibitory effect that reliably suppresses pathogenic bacteria and Candida albicans.
3Reliability
If Lactobacilli strains are used for probiotic treatment, then microbial balance improvement is achieved, but the adherence to mucosal membranes is not sufficient for effective colonization
Solution Approach 1:
The patent applies parameter changes by selecting Lactobacillus strains with optimized surface properties and adhesion molecules. The strains are characterized for their ability to bind to specific receptors on mucosal epithelial cells, with measured adhesion rates that enable effective colonization. This parameter optimization resolves the contradiction between adherence capability and colonization productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These strains effectively colonize mucosal membranes, suppress the growth of Candida albicans and Gram-negative pathogenic bacteria, and demonstrate strong inhibitory activity, making them suitable for treating or preventing vaginal, urinary-tract, and gastrointestinal infections.
Implementation Method 1
produce hydrogen peroxide
Implementation Method 2
exhibit strong adherence to mucosal membranes
Implementation Method 3
production of inhibitory compounds such as organic acids
Implementation Method 4
production of inhibitory compounds such as organic acids, hydrogen peroxide, bacteriocins
Data Source
AI summary
Novel Lactobacilli strains, Lactobacillus acidophilus strain Lba EB01 (Lba EB01), Lactobacillus paracasei strain Lbp PB01 (Lbp PB01), Lactobacillus acidophilus strain Lba EB02, Lactobacillus plantarum strain Lbpl PB02, Lactobacillus stain Lbxx EB03 and Lactobacillus strain Lbxx PB03, and strains with essentially the same advantageous properties which alone or in combination can be used as probiotics or together with a prebiotic as a synbiotic. The invention also relates to pharmaceutical compositions, dairy products, functional foods, nutraceutical and products for personal care comprising the strains alone or in combination, as well as use of the strain for prevention or treatment of vaginal infections, urogenital infections and gastrointestinal diseases.